mitomycin ophthalmic (Rx)Brand and Other Names:Mitosol

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

  • 0.2mg/vial (contained within entire kit)
more...

Glaucoma Surgery

Indicated for as adjunct to ab externo glaucoma surgery

Sponges provided within the kit should be fully saturated with the entire reconstituted contents (see Administration)

A treatment area approximating 10mm x 6mm +/- 2mm should be treated with mitomycin ophthalmic

Apply fully saturated sponges equally to the treatment area, in a single layer, with the use of a surgical forceps

Keep the sponges on the treatment area for 2 minutes, and then remove and copious irrigate surgical site

Administration

Intended for topical application to the surgical site of glaucoma filtration surgery

Not for intraocular administration; if intraocular administration occurs, cell death may lead to corneal infarction, retinal infarction, and ciliary body atrophy

Reconstitution

  • Each vial contains a lyophilized mixture of mitomycin 0.2 mg and mannitol 0.4 mg
  • To reconstitute, add 1 mL of sterile water for injection, then shake to dissolve
  • If product does not dissolve immediately, allow to stand at room temperature until the product dissolves into solution
  • Following reconstitution, resulting solution has a pH of 5.0-8.0
  • Preparing sponges: See full prescribing information

Stability

  • Unreconstituted vials: Store at controlled room temperature (ie, 20-25°C [68-77°F]); avoid excessive heat and protect form light
  • Reconstituted vials: When reconstituted to concentration of 0.2 mg/mL, stable for 1 hr at room temperature

Handling & disposal

  • Procedures for proper handling and disposal of anticancer drugs should be followed
  • Appropriate containment and disposal devices are included in each kit

Pterygium (Orphan)

Prevention of recurrence of pterygium after its surgical excision

Orphan designation sponsor

  • Mobius Therapeutics, Inc; 1141 South 7th Street; St. Louis, MO 63104

Corneal Subepithelial Haze (Orphan)

Prevention of corneal subepithelial haze formation following surface ablation laser keratectomy

Orphan designation sponsor

  • Mobius Therapeutics, Inc; 1141 South 7th Street; St. Louis, MO 63104

Safety and efficacy not established

Next

Adverse Effects

Frequency Not Defined

Blebitis (eg, bleb ulceration, chronic bleb leak, encapsulated/cystic bleb, bleb-related infection, wound dehiscence, conjunctival necrosis, thin-walled bleb)

Corneal reactions (eg, corneal endothelial damage, epithelial defect, anterior synechiae, superficial punctuate keratitis, Descemet’s detachment, induced astigmatism)

Endophthalmitis

Hypotony that include choroidal reactions (eg, choroidal detachment, choroidal effusion, serous choroidal detachment, suprachoroidal hemorrhage, hypotony maculopathy, presence of supraciliochoroidal fluid, hypoechogenic suprachoroidal effusion)

Inflammation (eg, iritis, fibrin reaction)

Cataract development, cataract progression, capsule opacification, capsular constriction and/or capsulotomy rupture, posterior synechiae

Retinal pigment epithelial tear, retinal detachment (serous and rhegmatogenous)

Wound dehiscence

Vascular (eg, hyphema, central retinal vein occlusion, hemiretinal vein occlusion, retinal hemorrhage, vitreal hemorrhage and blood clot, subconjunctival hemorrhage, disk hemorrhage)

Other reactions (macular edema, sclera thinning or ulceration, intraocular lens capture, disk swelling, malignant glaucoma, lacrimal drainage system obstruction, ciliary block, corneal vascularization, visual acuity decrease, cystic conjunctival degeneration, upper eyelid retraction, dislocated implants, severe loss of vision)

Previous
Next

Warnings

Contraindications

Hypersensitivity

Women who are or may become pregnant during therapy

Cautions

Cytotoxic agent; use in concentrations >0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation

Direct contact with the corneal endothelium will result in cell death

Associated with an increased instance of postoperative hypotony

Use in phakic patients has been correlated to a higher instance of lenticular change and cataract formation

Previous
Next

Pregnancy & Lactation

Pregnancy Category: X

Lactation: Unknown whether distributed in breast milk; a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Mechanism of Action

Inhibits synthesis of deoxyribonucleic acid (DNA); guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking

Cellular RNA and protein synthesis may also be suppressed

Absorption

Systemic exposure following ocular administration is unknown, but is expected to be multiple orders of magnitude lower than those achieved by IV administration

Metabolism

Cleared from ophthalmic tissue after intraoperative topical application and irrigation, as metabolism occurs in other affected tissues; systemic clearance is affected primarily by metabolism in the liver

Elimination

Excretion: Urine 10% (as unchanged)

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.